Evaluation of intense pulse light (IPL) for melasma: Efficacy, safety and patient experience.
DOI:
https://doi.org/10.29309/TPMJ/2023.30.09.7645Keywords:
IPL, Melasma, mMASI Score, Patient Experience, Treatment Efficacy, Treatment SafetyAbstract
Objective: To evaluate the efficacy and safety and patient experience of Intense pulse light (IPL) in our population. Study Design: Quasi-experimental. Setting: Department of Dermatology, HIT Hospital. Period: December 2022 to May 2023. Material & Methods: 34 females with melasma fulfilling the inclusion criteria were selected for this study. Exclusion criteria include thyroid disease, pregnant and lactating mothers, history of photosensitivity and retinoid intake. mMASI-1 was calculated before treatment. Treatment comprises of 4 sessions of IPL 2 week’s apart mMASI-2 was again calculated 2 weeks after the last session. Side effect were monitored, and improvement in mMASI score was assessed using a 4-point scale (Poor, Fair, Good, and Excellent). Additionally, the treatment experience reported by patient was evaluated using a 4-point scale (Not Satisfactory, Satisfactory, Substantial, and Remarkable). Results: Results of this study had shown a decrease in the mean baseline mMASI (modified Melasma Area and Severity Index) score from 14.22±5.32 to mMASI II 7.41±3.5, which was recorded two weeks after the last IPL session. The p-value, was found to be statistically significant (<0.000). Conclusion: IPL is a valuable treatment option for melasma, offering a significant improvement in pigmentation. It is well tolerated and associated with minimal side effects.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 The Professional Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.